Compare ClearPoint Neuro Inc (CLPT) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Wynn Resorts, Limited — how do they compare? ClearPoint Neuro Inc trades at $15.98 (market cap $478.63M), while Wynn Resorts, Limited trades at $96.85 (market cap $9.95B). The key difference: Wynn Resorts, Limited is far larger — about 20.8× ClearPoint Neuro Inc's market cap, and Wynn Resorts, Limited pays a 1.04% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | WYNN | |
|---|---|---|
Market Cap | $478.63M | $9.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $133.34 |
52-Week Low | $8.66 | $94.78 |
Enterprise Value | $506.63M | $20.32B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Wynn Resorts (WYNN) trades at $97.13, down 2.65% today, amid bearish technical signals and recent earnings misses. The stock faces margin pressure despite revenue growth, with net income margin declining to 5.14% in 2025. Analyst consensus remains bullish with a $134.30 price target, though technical indicators show resistance near $99-$103. Recent news highlights Q2 2026 earnings anticipation and luxury segment strength.
Outlook: Long-term potential exists via luxury focus and Macau recovery, but near-term risks include debt load ($10.5B), competitive pressures, and volatile earnings. Investors should weigh high analyst optimism against technical weakness and margin trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
